| AVY |
Report |
Adjusted EPS (Q2 2026) |
MISS |
pred ~$2.43 vs. cons $2.46 |
MEDIUM |
| AVY |
Report |
Revenue (Q2 2026) |
MISS |
pred ~$2.27B vs. cons $2.295B |
MEDIUM |
| AVY |
Report |
Organic Sales Growth (Q2 2026) |
MISS |
pred ~0.5% vs. cons ~2.0% |
LOW |
| AVY |
Guide |
Q3 2026 Adjusted EPS guidance |
LOWER |
guide ~$2.50 vs. cons $2.58 (Q3 2026) |
MEDIUM |
| AVY |
Guide |
FY2026 Adjusted EPS guidance (full-year range) |
UNCHANGED |
guide ~$9.95 vs. cons $10.05 (FY2026) |
LOW |
| AVY |
Guide |
Intelligent Labels 2H26 growth commentary |
UNCHANGED |
guide ~4-5% 2H26 growth vs. ~3% prior-year comp (2H2026 vs 2H2025) |
LOW |
| AVY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| AVY |
Return |
5-day cumulative residual |
-5.5% (FOLLOW-THROUGH) |
Stock rallied ~9% into the print (from $155 to $169 before settling near $166), pricing in an optimistic beat-and-raise scenario despite management's own guidance implying a sequential EPS plateau from the prebuy unwind and a genuine high-single-digit raw-material inflation shock. A likely modest EPS/revenue miss plus explicit commentary on price-cost lag persisting into Q3 gives sell-side analysts reason to trim Q3/FY26 estimates even if Q2 prints roughly in line, while any hedging on the Intelligent Labels second-half ramp (Walmart food rollout) removes the key re-rating catalyst bulls were counting on. With valuation already stretched into the print and limited room for disappointment, initial downside is likely to extend over the following days as consensus numbers get revised down rather than stabilize. |
MEDIUM |